Journal article
In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status.
Abstract
SOURCE CITATION: Filippatos G, Butler J, Farmakis D, et al. Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes. Circulation. 2022;146:676-86. 35762322.
Authors
Fudim M; Van Spall HGC
Journal
Annals of Internal Medicine, Vol. 175, No. 10,
Publisher
American College of Physicians
Publication Date
October 2022
DOI
10.7326/j22-0075
ISSN
1056-8751